Search results for "Pharmacokinetics"

showing 10 items of 458 documents

IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and ov…

2016

Orally administered drugs are subject to a number of barriers impacting bioavailability (Foral), causing challenges during drug and formulation development. Physiologically-based pharmacokinetic (PBPK) modelling can help during drug and formulation development by providing quantitative predictions through a systems approach. The performance of three available PBPK software packages (GI-Sim, Simcyp®, and GastroPlus™) were evaluated by comparing simulated and observed pharmacokinetic (PK) parameters.Since the availability of input parameters was heterogeneous and highly variable, caution is required when interpreting the results of this exercise. Additionally, this prospective simulation exer…

Physiologically based pharmacokinetic modellingChemistryBiopharmaceuticsDrug Evaluation PreclinicalArea under the curveAdministration OralPharmaceutical ScienceModels Biological030226 pharmacology & pharmacyBiopharmaceuticsBioavailabilityClinical studyToxicology03 medical and health sciences0302 clinical medicineIntestinal AbsorptionPharmaceutical PreparationsPharmacokineticsCompounding030220 oncology & carcinogenesisStatisticsHumansComputer SimulationImmediate releaseForecastingEuropean Journal of Pharmaceutical Sciences
researchProduct

Oral biopharmaceutics tools – Time for a new initiative – An introduction to the IMI project OrBiTo

2013

OrBiTo is a new European project within the IMI programme in the area of oral biopharmaceutics tools that includes world leading scientists from nine European universities, one regulatory agency, one non-profit research organization, four SMEs together with scientists from twelve pharmaceutical companies. The OrBiTo project will address key gaps in our knowledge of gastrointestinal (GI) drug absorption and deliver a framework for rational application of predictive biopharmaceutics tools for oral drug delivery. This will be achieved through novel prospective investigations to define new methodologies as well as refinement of existing tools. Extensive validation of novel and existing biopharm…

Physiologically based pharmacokinetic modellingComputer scienceProcess (engineering)Chemistry Pharmaceuticalmedia_common.quotation_subjectAdministration OralPharmaceutical SciencePharmacologyModels BiologicalPermeabilityQuality by DesignBiopharmaceuticsAnimalsHumansComputer SimulationPharmacokineticsQuality (business)Product (category theory)Program Developmentmedia_commonDosage FormsActive ingredientbusiness.industryBiopharmaceuticsGastrointestinal TractEngineering managementIntestinal AbsorptionPharmaceutical PreparationsSolubilityNew product developmentbusinessEuropean Journal of Pharmaceutical Sciences
researchProduct

Predicting Pharmacokinetics of Multisource Acyclovir Oral Products Through Physiologically Based Biopharmaceutics Modeling.

2021

Abstract Highly variable disposition after oral ingestion of acyclovir has been reported, although little is known regarding the underlying mechanisms. Different studies using the same reference product (Zovirax ®) showed that Cmax and AUC were respectively 44 and 35% lower in Saudi Arabians than Europeans, consistent with higher frequencies of reduced-activity polymorphs of the organic cation transporter (OCT1) in Europeans. In this study, the contribution of physiology (i.e., OCT1 activity) to the oral disposition of acyclovir immediate release (IR) tablets was hypothesized to be greater than dissolution. The potential role of OCT1 was studied in a validated physiologically-based biopharm…

Physiologically based pharmacokinetic modellingIn vitro dissolutionChemistryBiopharmaceuticsCmaxPharmaceutical ScienceAcyclovirBioequivalencePharmacologyBiopharmaceuticsOral ingestionPharmacokineticsSolubilityTherapeutic EquivalencyImmediate releaseTabletsJournal of pharmaceutical sciences
researchProduct

Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making

2021

Atorvastatin (ATS) is the gold-standard treatment worldwide for the management of hypercholesterolemia and prevention of cardiovascular diseases associated with dyslipidemia. Physiologically based pharmacokinetic (PBPK) models have been positioned as a valuable tool for the characterization of complex pharmacokinetic (PK) processes and its extrapolation in special sub-groups of the population, leading to regulatory recognition. Several PBPK models of ATS have been published in the recent years, addressing different aspects of the PK properties of ATS. Therefore, the aims of this review are (i) to summarize the physicochemical and pharmacokinetic characteristics involved in the time-course o…

Physiologically based pharmacokinetic modellingModel predictionAtorvastatinPopulationPharmaceutical ScienceReviewTarget populationComputational biologyP-glycoprotein030226 pharmacology & pharmacy03 medical and health sciencesPharmacy and materia medica0302 clinical medicinePharmacokineticsmedicineopen acid formeducationeducation.field_of_studybusiness.industrysolubilityatorvastatinactive metabolitesRS1-441lactonizationDose optimizationMetabolic enzymes030220 oncology & carcinogenesisbusinessmedicine.drugPharmaceutics
researchProduct

Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice

2020

MBQ-167 is a dual inhibitor of the Rho GTPases Rac and Cdc42 that has shown promising results as an anti-cancer therapeutic at the preclinical stage. This drug has been tested in vitro and in vivo in metastatic breast cancer mouse models. The aim of this study is to develop a physiologically based pharmacokinetic/pharmacodynamic (PBPK-PD) model of MBQ-167 to predict tumor growth inhibition following intraperitoneal (IP) administration in mice bearing Triple Negative and HER2+ mammary tumors. PBPK and Simeoni tumor growth inhibition (TGI) models were developed using the Simcyp V19 Animal Simulator. Our developed PBPK framework adequately describes the time course of MBQ-167 in each of the mo…

Physiologically based pharmacokinetic modellinglcsh:RS1-441Pharmaceutical ScienceSpleenPharmacologyArticlelcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinebreast cancerPharmacokineticsIn vivomedicinePotency030304 developmental biology0303 health sciencesMammary tumorbusiness.industryMBQ-167medicine.diseaseMetastatic breast cancermedicine.anatomical_structure030220 oncology & carcinogenesisPharmacodynamicsRac inhibitorphysiologically based pharmacokinetic modelingbusinessPharmaceutics
researchProduct

Sex differences in estimation of time intervals and in reaction time are removed by moderate but not high doses of caffeine in coffee

2002

Estimation of the passage of time in the seconds-to-minutes range and reaction time are strongly dependent on a hypothetical internal clock. Dopamine is the neurotransmitter most closely related to the rate of this clock. Caffeine, probably the most consumed drug in the world, leads to an augmentation of dopamine neurotransmission. In this study coffee, which reproduces the conditions under which caffeine is normally ingested, containing 3, 75, 150 or 300 mg of caffeine, was given to healthy male and female volunteers. A computerized time estimation and reaction time test was carried out 50 min after ingestion. Sex differences in placebo control subjects (who took decaffeinated coffee with …

PhysiologyCoffee consumptionPlaceboControl subjectsToxicologyPsychiatry and Mental healthchemistry.chemical_compoundNeurologyPharmacokineticschemistryTime estimationHigh dosesIngestionPharmacology (medical)Neurology (clinical)PsychologyCaffeineHuman Psychopharmacology: Clinical and Experimental
researchProduct

Hemodilution in isolated tumor perfusion.

1984

Experiments are performed to study the influence of local hemodilution on tumor blood flow, oxygen availability in tumor tissue and O2 consumption of cancer cells. The results obtained clearly show that hemodilution in isolated tumor perfusion can distinctly improve nutritive blood flow through solid tumors. This can be utilized to enhance pharmacokinetics of antitumor drugs. Due to the improved metabolic status, the pharmacodynamics of some antitumor drugs should also be enhanced. To achieve a maximum improvement of the O2 supply to the tumor, hematocrit values should not be decreased below 0.20.

PhysiologyPharmacologyHematocritMicrocirculationOxygen ConsumptionPharmacokineticsCarcinosarcomaPhysiology (medical)CarcinosarcomamedicineAnimalsHemodilutionmedicine.diagnostic_testbusiness.industryMicrocirculationRats Inbred StrainsBlood flowmedicine.diseaseKidney NeoplasmsRatsmedicine.anatomical_structureHematocritRegional Blood FlowPharmacodynamicsCancer cellVascular resistanceVascular ResistancebusinessBlood Flow VelocityBiorheology
researchProduct

Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder …

2020

Background: The aim of this analysis was to characterize the pharmacokinetics (PK) of sublingual buprenorphine (BUP) and its metabolites (buprenorphine glucuronide

PopulationCmaxbuprenorphine/naloxone sublingual filmlcsh:RS1-441Pharmaceutical SciencePharmacology030226 pharmacology & pharmacyArticlelcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticspopulation pharmacokineticsNaloxonemedicine030212 general & internal medicineDosingNorbuprenorphinePuerto Ricanseducationeducation.field_of_studyopioid use disorder (OUD)business.industrypopPKchemistryGlucuronidebusinessSuboxonepharmacokineticsmedicine.drugBuprenorphinecompartmental modelingPharmaceutics
researchProduct

Levofloxacin effect on erlotinib absorption. Evaluation of the interaction in undernutrition situations through population pharmacokinetic analysis i…

2017

The main objective of this study was to develop a pharmacokinetic model in order to describe the intestinal absorption of erlotinib in rat and to quantify the interaction of levofloxacin on this process in well- and under-nourished rats. Absorption studies were performed in male Wistar rats. Concentration-time profiles in proximal and distal intestine were analysed through non-linear mixed effect modelling using the NONMEM software version 7.3. Simulations were performed in order to explore the influence of covariates on the apparent absorption rate constant. A passive absorption and an active secretion process best-described erlotinib absorption from lumen to enterocyte. The developed mode…

PopulationPharmaceutical SciencePharmacology030226 pharmacology & pharmacyIntestinal absorption03 medical and health sciences0302 clinical medicineIntestinal mucosaPharmacokineticsmedicineheterocyclic compoundsPharmacology (medical)educationErlotinib HydrochlorideneoplasmsPharmacologyeducation.field_of_studybusiness.industryGeneral MedicineDrug interactionrespiratory tract diseasesNONMEM030220 oncology & carcinogenesisErlotinibbusinessmedicine.drugBiopharmaceutics & Drug Disposition
researchProduct

Evaluation of [11C]Metergoline as a PET Radiotracer for 5HTR in Nonhuman Primates

2010

Metergoline, a serotonin receptor antagonist, was labeled with carbon-11 in order to evaluate its pharmacokinetics and distribution in non-human primates using positron emission tomography. [{sup 11}C]Metergoline had moderate brain uptake and exhibited heterogeneous specific binding, which was blocked by pretreatment with metergoline and altanserin throughout the cortex. Non-specific binding and insensitivity to changes in synaptic serotonin limit its potential as a PET radiotracer. However, the characterization of [{sup 11}C]metergoline pharmacokinetics and binding in the brain and peripheral organs using PET improves our understanding of metergoline drug pharmacology.

PrimatesMetergolinemedicine.medical_specialtyBiodistributionClinical BiochemistryPharmaceutical ScienceBiochemistryArticlechemistry.chemical_compoundPharmacokineticsInternal medicineDrug DiscoverymedicineDistribution (pharmacology)Serotonin receptor antagonistAnimalsTissue DistributionCarbon RadioisotopesMolecular BiologyChemistryOrganic ChemistryAntagonistBrainEndocrinologyPositron-Emission TomographyReceptors SerotoninAltanserinMetergolineMolecular MedicineSerotoninRadiopharmaceuticalsProtein Binding
researchProduct